Polariton
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Polariton - overview
Established
2020
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Established in 2020 and based in Suzhou, China, Polariton is a biotechnology company whose main business is the development, production and sales of high-end life science instruments. Mr. Liu Jing, the founder of the company, graduated from Southeast University with a degree in Biomedical Engineering, and then received his Ph. D.
from the Max Planck Institute of Polymer Science in Germany. In June 2023, the company closed a round of pre-series A funding. The company mainly develops and produces life science series instruments, mainly including surface plasmon resonance (SPR) molecular interactions analyzer. Surface plasmon resonance (SPR), a non-labeled real-time detection technology based on optical, microfluidic and biosensor, enables dynamic monitoring and analysis of biomolecular interactions.
The company will use the pre-series A funding for the development of products such as the company's own intellectual property SPR molecular interoperability instrument.
Current Investors
Shandong High-tech Investment Corporation, ABclonal, Inc.
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Medical Devices & Equipment
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.